NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
BackgroundParkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra and pathological aggregation of α-Synuclein (α-Syn). Although Irisin has shown neuroprotective effects in acute MPTP-induced and α-Syn preformed fibrils (PFFs) propagation models, its therapeutic effects in a chronic α-Syn overexpression model remain incompletely defined.MethodsIn the present study, we evaluated the effects of AAV8-Irisin delivered either peripherally via tail vein injection or centrally via direct intranigral co-administration in the AAV9-A53T mouse model.ResultsUnder the tested doses, routes, and intervention schedule, neither peripheral nor intranigral AAV8-Irisin delivery produced statistically significant improvements in behavioral performance, dopaminergic neuron survival, α-Synuclein pathology, glial activation, or AQP4 polarization; however, numerical trends were observed in select measures, including motor coordination and TH-positive neuron counts.ConclusionThese findings suggest that, under the current experimental conditions, a clear neuroprotective benefit of Irisin was not readily detectable in this model. Whether modest effects might emerge under different exposure levels, intervention windows, or adequately powered designs remains unknown.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.